Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer

Therapeutic Delivery

Volumn 5, Issue 2, 2014, Pages 129-138

  Yanagihara, Kazuyoshi ^a,b   Takigahira, Misato ^c   Kubo, Takanori ^b   Ochiya, Takahiro ^d   Hamaguchi, Tetsuya ^c   Matsumura, Yasuhiro ^c  

^a NATIONAL CANCER CENTER   (Japan)

^b YASUDA WOMEN'S UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIRTECAN; IRINOTECAN; LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METASTASIS; MICELLE; MOUSE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FEMALE; GENES, REPORTER; HUMANS; LIVER NEOPLASMS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, SCID; MICELLES; STOMACH NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893318278     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.143     Document Type: Article

References (45)

1. Shirabe K, Shimada M, Matsumata T et al. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 50, 1560-1563 (2003).
2. Marrelli D, Roviello F, de Stefano A et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J. Am. Coll. Surg. 198, 51-58 (2004).
3. Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric cancer: a review. Gastric Cancer 9, 74-81 (2006).
4. Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth, and metastasis of human renal cancer in nude mice. Cancer Metastasis Rev. 9, 149-165 (1990).
5. Furukawa T, Kubota T, Watanabe M, Kitagima M, Hoffman RM. A novel patient-like treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res. 53, 3070-3072 (1993).
6. Vieweg J, Rosenthal FM, Bannerji R et al. Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54, 1760-1765 (1994).
7. Kleinerman DI, Dinney CP, Zhang WW, Lin SH, van NT, Hsieh JT. Suppression of human-bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res. 56, 3431-3435 (1996).
8. Furukawa T, Kubota T, Watanabe M et al. A metastatic model of human colon cancer constructed using cecal implantation of cancer tissue in nude mice. Surg. Today 23, 420-423 (1993).
9. Hoffman, RM. Orthotopic metastatic models of anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs 17, 343-359 (1999).
10. Yamaguchi K, Ura H, Yasoshima T, Shishido T, Denno R, Hirata K. Liver metastatic model for human gastric cancer established by orthotopic tumour cell implantation. World J. Surg. 25, 131-137 (2001).
11. Yanagihara K, Takigahira M, Tanaka H et al. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci. 96, 323-332 (2005).
12. Enomoto T, Oda T, Aoyagi Y et al. Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells. Cancer Res. 66, 11131-11139 (2006).
13. Amoh Y, Bouvet M, Li L et al. Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-linked-GFP mice. Clin. Exp. Metastasis 23, 315-322 (2006).
14. Frampas E, Maurel C, Thedrez P et al. The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody. Nucl. Med. Commun. 32, 147-154 (2011).
15. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl Cancer Inst. 46, 789-795 (1971).
16. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res. 32, 2643-2650 (1972).
17. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54, 461-470 (1970).
18. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 56, 515-521 (1972).
19. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
20. Koizumi F, Kitagawa M, Negishi T et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 66, 10048-10056 (2006).
21. Sumitomo M, Koizumi F, Asano T et al. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 68, 1631-1635 (2008).
22. Nakajima TE, Yasunaga M, Kano Y et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int. J. Cancer 122, 2148-2153 (2008).
23. Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Enhanced distribution of NK012, a polymeric micelle encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci. 99, 1258-1264 (2008).
24. Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int. J. Cancer 124, 2505-2511 (2009).
25. Takahashi A, Ohkochi N, Yasunaga M et al. Detailed distribution of NK012, an SN-38-Incoporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases. Clin. Cancer Res. 16, 4822-4831 (2010).
26. Kuroda J, Kuratsu J, Yasunaga M et al. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin. Cancer Res. 16, 521-529 (2010).
27. Nakajima TE, Yanagihara K, Takigahira M et al. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res. 68, 9318-9322 (2008).
28. Yanagihara K, Tanaka H, Takigahira M et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci. 95, 575-582 (2004).
29. Carbal H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum (II) (DACHPt)-loaded polymeric micelles. J. Control. Release 101, 223-232 (2005).
30. Yanagihara K, Kamada N, Tsumuraya M, Amano F. Establishment and characterization of a human gastric scirrhous carcinoma cell line in serum-free chemically defined medium. Int. J. Cancer 54, 200-207 (1993).
31. Yanagihara K, Takigahira M, Takeshita F et al. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer Res. 66, 7532-7539 (2006).
32. Yanagihara K, Nii M, Tsumuraya M, Numoto M, Seito T, Seyama T. A radiation-induced murine ovarian granulose cell tumor line: introduction of v-ras gene potentiates a high metastatic ability. Jpn J. Cancer Res. 86, 347-356 (1995).
33. Tiberio GA, Coniglio A, Marchet A et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur. J. Surg. Oncl. 35, 486-491 (2009).
34. Thelen A, Jonas S, Benckert C et al. Liver resection for metastatic gastric cancer. Eur. J. Surg. Oncol. 34, 1328-1334 (2008).
35. Nashimoto A, Yabusaki H, Nakagawa S. Proper follow-up schedule after curative gastric surgery. Jpn J. Cancer Chemother. 36, 1402-1407 (2009).
36. Yasoshima T, Denno R, Kawaguchi S et al. Establishment and characterization of human gastric carcinoma lines with high metastatic potential in the liver: changes in integrin expression associated with the ability to metastasize in the liver of nude mice. Jpn J. Cancer Res. 87, 153-160 (1996).
37. Nakanishi H, Yasui K, Ikehara Y et al. Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clin. Exp. Metastasis 22, 137-147 (2005).
38. Yokoyama H, Ikehara Y, Kodera Y et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br. J. Cancer 95, 1504-1513 (2006).
39. Shen X, Jin W, Cui H et al. Cellular adjustment of gastric cancer for hepatic metastasis in successive orthotopic implantation model. Cancer Biol. Ther. 5, 1313-1319 (2006).
40. Matsuoka T, Adair JE, Lih FB et al. Elevated dietary lioleic acid increases gastric carcinoma cell invasion and metastasis in mice. Br. J. Cancer 103, 1182-1191(2010).
41. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
42. Jager E, van der Velden VH, te Marvelde JG, Walter RB, Agur Z, Vainstein V. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. 6(9), e24265 PLoS ONE (2011).
43. Li Y, Li B, Zhang Y, Xiang CP, Li YY, Wu XL. Serial observations on an orthotopic gastric cancer model constructed using improved implantation technique. World J. Gastroenterol. 17, 1442-1447 (2011).
44. Noguchi Y, Wu J, Duncan R et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J. Cancer Res. 89, 307-314 (1998).
45. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).